Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.
Concerns about the legitimacy of pyrilutamide solutions from Farmacia Tristaina due to low prices and lack of testing. Users suggest using Jano testing for product verification.
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
A 23-year-old male is considering starting Finasteride for hair loss after experiencing persistent shedding and hairline recession, with bloodwork showing normal testosterone levels but low DHEA-S and Vitamin D. He plans to discuss DHEA supplementation with his doctor and has already started Vitamin D supplementation.
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.
The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.
Dutasteride treatment may decrease sperm concentration, but levels remain above WHO recommendations and recover after discontinuation. The study has limitations, including small sample size and lack of pre-treatment sperm data, and does not assess other fertility factors.
Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.
The Ordinary multipeptide hair serum is used alongside treatments like minoxidil, topical finasteride, and derma rolling, with some users reporting hair thickening and vellus hair regrowth. However, experiences vary, and some users are skeptical due to the lack of solid evidence and mixed efficacy reports.
Using finasteride and peptides, including GHK-Cu, improved hair thickness and regrowth. The user also used a KLOW blend and CJC/IPA for better sleep and recovery.
The post and conversation are about the user's high testosterone levels and their worsening hair loss despite trying various treatments. They are considering using low doses of anti-androgens to lower their testosterone levels as a potential solution.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.
People are discussing obtaining and testing PP405 for hair loss treatment, with concerns about its purity and effectiveness. Some are considering delaying hair transplants, while others suggest using existing treatments like finasteride and minoxidil.
The user is considering starting a topical treatment for hair loss, using a spray containing 0.3% finasteride, 5% minoxidil, and 0.01% tretinoin. They are questioning the dosage and considering reducing the application to achieve 0.15% finasteride and 5% minoxidil.
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.
27-year-old female experiences aggressive hair thinning and hirsutism despite normal testosterone levels. Spironolactone and 2% minoxidil were ineffective; high DHEA sulfate levels may be the cause.
The conversation is about finding cheaper alternatives for hair loss treatments. Specific treatments mentioned include finasteride and L'Oréal Paris Elvital Hyaluron Plump Leave-In Spray.
The user has been using 0.25% topical finasteride for eight months with slight improvement and is considering switching to oral finasteride for convenience and potentially better results. Increasing the topical concentration to 0.33% or 0.5% is also an option, but oral finasteride may have more systemic side effects.
A man shared his 6-month hair regrowth progress using 0.5mg of finasteride daily and recently increased the dose to 1mg. Users discussed the effectiveness of the treatment and shared their own experiences with hair loss treatments.
A user was recommended PRP and exosomes for hair loss and asked about combining them and places to get the treatment in the UK. Other users suggested starting with finasteride and minoxidil due to the high cost and variable success of PRP and exosomes.
Elevated liver enzymes were reported from taking finasteride and minoxidil. The doctor advised stopping oral minoxidil and taking finasteride every other day.
Topical dutasteride with microneedling is effective for androgenetic alopecia, improving hair thickness and density. Further research is needed to confirm long-term efficacy.
The post discusses the experiences of individuals with diffuse hair thinning using finasteride, with many reporting no improvement or worsening conditions after 6 months. Various suggestions include persisting with the treatment, checking for underlying conditions, adding minoxidil for volume, adjusting dosage, and considering other potential causes like autoimmune responses and inflammation.
The conversation discusses the potential effectiveness and risks of using topical finasteride for hair loss, with considerations about using DMSO as a vehicle for application. Concerns are raised about DMSO's safety, absorption issues, and the systemic effects of topical finasteride.
The efficacy of low doses of finasteride to reduce scalp DHT, and whether studies showing a 61% reduction are reflected in actual results. Replies discussed hair growth as an unintended consequence of minoxidil and finasteride use, as well as self-selective bias, potential side effects, and that studies measure effectiveness by hair count changes rather than DHT inhibition.
The user reported high estradiol levels after one month of using finasteride for hair loss. They discussed potential side effects and adjustments to their treatment plan.
A user is discussing making a DIY topical finasteride solution using ingredients like water, alcohol, propylene glycol, ethanol, and glycerin, and is concerned about the stability of the mixture. Other users suggest that the solution will work and discuss the importance of propylene glycol for drug dissolution and factors like temperature and light affecting finasteride stability.
Switching from propylene glycol to glycerin in topical finasteride may reduce systemic absorption and side effects while maintaining local scalp DHT suppression. Concerns exist about glycerin's ability to deliver the full dose to hair follicles.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.